Insomnia in Women: Causes, Consequences, and Evidence-Based Solutions

Insomnia—difficulty falling asleep, staying asleep, or non-restorative sleep—affects women 1.5–2x more often than men due to hormonal, psychosocial, and biological factors.

Key Contributing Factors in Women

• Hormonal fluctuations: Menstrual cycle (premenstrual), pregnancy (especially 3rd trimester), perimenopause/menopause (hot flashes, night sweats, estrogen decline)
• Psychiatric comorbidity: Anxiety and depression (both 2x more prevalent in women) are bidirectionally linked to insomnia
• Psychosocial stress: Caregiving burden, work-family conflict, socioeconomic pressure
• Medical conditions: Thyroid disorders, chronic pain (fibromyalgia, migraine), urinary frequency, GERD
• Medications: SSRIs/SNRIs, stimulants, corticosteroids, decongestants, some antihypertensives
• Circadian rhythm shifts: Advanced sleep phase with aging; delayed phase in younger women

Consequences of Chronic Insomnia

• Daytime fatigue, impaired concentration, memory lapses
• Mood dysregulation, irritability
• Increased cardiovascular risk, metabolic dysregulation
• Weakened immune function
• Higher accident/injury risk
• Reduced quality of life

Evidence-Based Treatments

First-Line: CBT-I (Cognitive Behavioral Therapy for Insomnia)

• Gold standard: 70–80% response; durable benefits; no medication risks
• Components: Sleep restriction, stimulus control, cognitive restructuring, relaxation training, sleep hygiene education
• Delivery: Individual, group, digital (e.g., Sleepio, CBT-I Coach), telehealth

Lifestyle Modifications (Sleep Hygiene)

• Consistent sleep/wake times (even weekends)
• Dark, cool, quiet bedroom; no screens 60 min before bed
• Caffeine cutoff by 12–2 PM; alcohol avoidance (fragments sleep)
• Regular exercise (not within 3 hrs of bedtime)
• Wind-down routine (reading, stretching, meditation)

Pharmacologic Options (When CBT-I Insufficient/Unavailable)

• Short-term, lowest effective dose; avoid long-term benzodiazepines/Z-drugs (dependence, falls, cognitive risk)
• Melatonin receptor agonists: Ramelteon
• Orexin receptor antagonists: Suvorexant, lemborexant, daridorexant
• Low-dose doxepin (3–6 mg): Sleep maintenance
• Off-label: Trazodone, mirtazapine, gabapentin (if comorbid indications)

Hormonal Considerations

• Menopausal hormone therapy (MHT) may improve sleep if vasomotor symptoms drive insomnia
• Individualize risk/benefit; not indicated solely for sleep

When to Seek Professional Help

• Insomnia ≥3 nights/week for ≥3 months (chronic insomnia disorder)
• Daytime impairment
• Self-help strategies ineffective after 4–6 weeks
• Suspected sleep apnea (snoring, witnessed apneas, unrefreshing sleep)

Insomnia is treatable. Start with CBT-I; involve a sleep specialist or behavioral sleep medicine provider for persistent cases.